Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Depreciation and Depletion (2016 - 2017)

Historic Depreciation and Depletion for UroGen Pharma (URGN) over the last 2 years, with Q4 2017 value amounting to $58000.0.

  • UroGen Pharma's Depreciation and Depletion fell 2839.51% to $58000.0 in Q4 2017 from the same period last year, while for Dec 2017 it was $243000.0, marking a year-over-year change of. This contributed to the annual value of $207000.0 for FY2017, which is 281.69% down from last year.
  • Per UroGen Pharma's latest filing, its Depreciation and Depletion stood at $58000.0 for Q4 2017, which was down 2839.51% from $17000.0 recorded in Q3 2017.
  • UroGen Pharma's 5-year Depreciation and Depletion high stood at $87000.0 for Q2 2017, and its period low was $17000.0 during Q3 2017.